The role of MRI/TRUS fusion biopsy in the diagnosis of clinically significant prostate cancer
Open Access
- 1 January 2020
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 12
Abstract
Background: The aim of this work is to evaluate the detection rate of magnetic resonance imaging/transrectal ultrasound (MRI/TRUS) fusion-guided biopsy for clinically significant prostate cancers (Cs PCas), with particular interest in biopsy-naive patients and patients in active surveillance. MRI-targeted biopsy improves cancer detection rate (DR) in patients with prior negative biopsies; the current literature focuses on biopsy naive patients. We also evaluated the pathologic concordance between biopsies and surgical specimens. Methods: MRI/TRUS fusion-guided biopsies were performed between February 2016 and February 2019. Patients with previous negative biopsies, biopsy-naive or in active surveillance (AS) were included. Cs PCas were defined through Epstein’s criteria. Results: A total of 416 men were enrolled. The overall DRs and Cs PCa DRs were 49% and 34.3%, respectively. Cs PCas were 17.2%, 44.9% and 73.4%, respectively for PI-RADS 3, 4 or 5. Among biopsy-naive patients, 34.8% were found to have a Cs PCa, while a 43.6% tumour upgrading was achieved in men with a low risk of PCa. In patients who underwent radical prostatectomy (RP), the concordance between biopsy Gleason score (GS) (bGS) and pathological GS (pGS) was 90.8%. Conclusion: Our study highlights the role of MRI/TRUS fusion prostate biopsy in the detection of PCa in patients with previous negative biopsies focusing on Cs PCa diagnosis. The MRI/TRUS fusion biopsy is also emerging as a diagnostic tool in biopsy-naïve patients and deserves a fundamental role in AS protocols. A greater concordance between bGS and pGS can be achieved with targeted biopsies.Keywords
This publication has 30 references indexed in Scilit:
- Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate CancerJAMA, 2015
- Multiparametric Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Targeted Biopsy of the Prostate: Preliminary Results of a Prospective Single-Centre StudyUrologia Internationalis, 2015
- Comparison of systematic transrectal biopsy to transperineal magnetic resonance imaging/ultrasound‐fusion biopsy for the diagnosis of prostate cancerBJU International, 2014
- Manually controlled targeted prostate biopsy with real‐time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: An early experienceInternational Journal of Urology, 2014
- A Prospective, Blinded Comparison of Magnetic Resonance (MR) Imaging–Ultrasound Fusion and Visual Estimation in the Performance of MR-targeted Prostate Biopsy: The PROFUS TrialEuropean Urology, 2014
- Target detection: Magnetic resonance imaging-ultrasound fusion–guided prostate biopsyUrologic Oncology: Seminars and Original Investigations, 2014
- Improving Detection of Clinically Significant Prostate Cancer: Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Guided Prostate BiopsyJournal of Urology, 2014
- Biopsy Criteria for Determining Appropriateness for Active Surveillance in the Modern EraUrology, 2014
- First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography‐guided biopsies for the diagnosis of localised prostate cancerBJU International, 2014
- MRI-targeted prostate biopsy: a review of technique and resultsNature Reviews Urology, 2013